title: GSK-3: A key regulatory target for ketamine's rapid antidepressant effects mediated by enhanced AMPA to NMDA throughput.
authors.affiliation: Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.
authors.forename: Carlos A
authors.initials: CA
authors.lastname: Zarate
authors.affiliation: Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.
authors.forename: Rodrigo
authors.initials: R
authors.lastname: Machado-Vieira
mesh_terms: D000928:Antidepressive Agents; D001714:Bipolar Disorder; D038362:Glycogen Synthase Kinase 3; D006801:Humans; D007649:Ketamine; D016202:N-Methylaspartate; D016194:Receptors, N-Methyl-D-Aspartate; D018350:alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid
chemical_list: D000928:Antidepressive Agents; D016194:Receptors, N-Methyl-D-Aspartate; D016202:N-Methylaspartate; D007649:Ketamine; D018350:alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; D038362:Glycogen Synthase Kinase 3
keywords: glycogen synthase kinase 3 (GSK-3); ketamine; α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)